Epiphany Biosciences Overview
- Year Founded
-
1998
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
Epiphany Biosciences General Information
Description
Developer of small molecule therapeutics platform designed to treat diseases of herpes virus origin. The company engages in the development of antiviral therapeutics to prevent the spread of the varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and hepatitis C virus (HCV), enabling researchers to prevent or cure the spread of pathogenic viruses.
Contact Information
Website
www.epiphanybio.comCorporate Office
- 1462 42nd Avenue
- Suite 2800
- San Francisco, CA 94122
- United States
Corporate Office
- 1462 42nd Avenue
- Suite 2800
- San Francisco, CA 94122
- United States
Epiphany Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 29-Sep-2021 | Completed | Generating Revenue | |||
| 4. Grant | 04-Apr-2017 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 14-Mar-2007 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Dec-1998 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 01-Jan-1998 | Completed | Generating Revenue |
Epiphany Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Epiphany Biosciences Patents
Epiphany Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260191871-A1 | Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses | Pending | 28-Nov-2022 | ||
| WO-2024118480-A1 | Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses | Inactive | 28-Nov-2022 | ||
| WO-2014047562-A2 | Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain | Inactive | 21-Sep-2012 | ||
| WO-2014047562-A3 | Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain | Inactive | 21-Sep-2012 | ||
| US-20150050241-A1 | Method of treating viral infections | Inactive | 21-Sep-2012 | A61K31/522 |
Epiphany Biosciences Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| CDIB BioScience Venture Management | Venture Capital | Minority | ||
| Global Trust Ventures | PE/Buyout | Minority | ||
| Windsor Bay Capital | Venture Capital | Minority |
Epiphany Biosciences FAQs
-
When was Epiphany Biosciences founded?
Epiphany Biosciences was founded in 1998.
-
Where is Epiphany Biosciences headquartered?
Epiphany Biosciences is headquartered in San Francisco, CA.
-
What industry is Epiphany Biosciences in?
Epiphany Biosciences’s primary industry is Biotechnology.
-
Is Epiphany Biosciences a private or public company?
Epiphany Biosciences is a Private company.
-
What is Epiphany Biosciences’s current revenue?
The current revenue for Epiphany Biosciences is .
-
How much funding has Epiphany Biosciences raised over time?
Epiphany Biosciences has raised $36.2M.
-
Who are Epiphany Biosciences’s investors?
, , CDIB BioScience Venture Management, Global Trust Ventures, and Windsor Bay Capital are 5 of 7 investors who have invested in Epiphany Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process